IP Library › Granted Patent US 10,350,185
Granted Patent B2
US 10,350,185 · App. 14/773,960 · Granted Jul 16, 2019

Materials and methods for improving lung function and for prevention and/or treatment of radiation-induced lung complications

Inventors: Sadasivan Vidyasagar (Gainesville, FL); Paul Okunieff (Gainesville, FL)
Assignee: University of Florida Research Foundation, Incorporated
A61K31/198A61K9/0053A61K31/405A61K33/14
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 10,350,185
App. No.
14/773,960
Granted
Jul 16, 2019
Kind
B2
Abstract

The subject invention provides therapeutic compositions and uses thereof for improving pulmonary function. In one embodiment, the therapeutic composition comprises one or more free amino acids selected from lysine, glycine, threonine, valine, tyrosine, aspartic acid, isoleucine, tryptophan, asparagine, and serine; and electrolytes. In one embodiment, the subject invention can be used to prevent or treat long-term lung complications induced by radiation.

Claims (8)

1. A method of improving lung function, wherein the method comprises administering, to a subject with a lung injury or a lung disease, an effective amount of a therapeutic composition consisting essentially of L-lysine, L-glycine, L-threonine, L-valine, L-tyrosine, L-aspartic acid, L-isoleucine, and L-serine; and optionally, therapeutically acceptable carriers, electrolytes, buffering agents, and flavoring agents.

2. The method, according to claim 1 , wherein the therapeutic composition is orally administered.

3. The method, according to claim 1 , wherein the subject is a human.

4. The method, according to claim 1 , wherein the composition does not comprise glutamine or methionine, or, if these ingredients are present, glutamine is present at a concentration of less than 300 mg/l and methionine is present at a concentration of less than 100 mg/l.

5. A method of improving lung function, wherein the method comprises administering, to a subject with a lung injury or a lung disease, an effective amount of a therapeutic composition consisting essentially of L-lysine, L-glycine, L-threonine, L-valine, L-tyrosine, L-aspartic acid, L-isoleucine, L-tryptophan, and L-serine; and optionally, therapeutically acceptable carriers, electrolytes, buffering agents, and flavoring agents.

6. The method, according to claim 5 , wherein the therapeutic composition is orally administered.

7. The method, according to claim 5 , wherein the subject is a human.

8. The method, according to claim 5 , wherein the composition does not comprise glutamine or methionine, or, if these ingredients are present, glutamine is present at a concentration of less than 300 mg/l and methionine is present at a concentration of less than 100 mg/l.

Assignments (1)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Sep 11, 2015
From: VIDYASAGAR, SADASIVAN; OKUNIEFF, PAUL
To: UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INCORPORATED
Reel/Frame 036539/0896 →
Continuity (2)
Provisional Application 61775754 · Mar 11, 2013
Related Publication 20160015664A1 · Jan 21, 2016